Shenzhen TargetRx Co., Ltd.
Quick facts
| Founded | 2014 |
|---|
Phase 3 pipeline
- TGRX-326 · Diabetes
TGRX-326 is a small molecule that targets the SGLT2 receptor. - TGRX-678 · Diabetes
TGRX-678 is a small molecule that targets the SGLT2 receptor. - TKI · Oncology
TKI inhibits tyrosine kinases to block cancer cell proliferation and survival.
Phase 1 pipeline
- [14C]TGRX-326
- [14C]TGRX-678
- cycle 1: reference drug
- cycle 1: treatment drug
- cycle 2: reference drug
- cycle 2: treatment drug
- cycle 3: reference drug
- cycle 3: treatment drug
- TGRX-1942
- TGRX-814
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Shenzhen TargetRx Co., Ltd.
What is Shenzhen TargetRx Co., Ltd.'s pipeline?
Shenzhen TargetRx Co., Ltd. has 3 drugs in Phase 3, 0 in Phase 2, 10 in Phase 1. Late-stage candidates include TGRX-326, TGRX-678, TKI.
When was Shenzhen TargetRx Co., Ltd. founded?
Shenzhen TargetRx Co., Ltd. was founded in 2014.
Related
- Sector hub: All tracked pharma companies